Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active-not-recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Carcinoma in Situ
• Invasive Breast Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING